Silkim Pharma
Novel Drugs Targeting Inflammatory Pathologies
Company Overview
Snapshot
Founded in March 2013 by Dror Chevion and Prof. Mordechai (Mottie) Chevion, Silkim Pharma operates with 1–10 employees. The company focuses on drug development and recently received a response from the FDA regarding its new drug against coronavirus in May 2020.
Business overview
Silkim Pharma is a Health Tech & Life Sciences company specializing in the development of novel drugs targeting inflammatory pathologies. The company's platform, derived from extensive investigation of animal models of human diseases, produces potent anti-inflammatory, strong iron-chelating, and antibiotic agents. These agents are designed to treat the causes and symptoms of multiple indications, serving the pharmaceutical sector within the broader healthcare and life sciences market.
Strategic signal
In May 2020, Silkim Pharma received a rapid response from the FDA concerning its new drug developed to combat coronavirus. This event signals the company's agility in addressing urgent global health crises and its capability to engage with regulatory bodies efficiently, indicating potential for accelerated drug development and market entry in critical areas.
Company Intelligence Q&A
- What is Silkim Pharma's primary focus?
- Silkim Pharma focuses on developing novel drugs that target inflammatory pathologies, utilizing a platform derived from extensive investigation of animal models of human diseases.
- Who founded Silkim Pharma?
- Silkim Pharma was co-founded by Dror Chevion and Prof. Mordechai (Mottie) Chevion.
- When was Silkim Pharma founded?
- Silkim Pharma was founded in March 2013.
- What significant regulatory milestone did Silkim Pharma achieve in 2020?
- In May 2020, Silkim Pharma received a response from the FDA regarding its new drug developed to combat coronavirus.
- What are the key properties of Silkim Pharma's drug platform?
- Silkim Pharma's drug platform produces agents that act as potent anti-inflammatory, strong iron-chelating, and antibiotic agents, which collectively address various indications.